New drugs for CML: are more to come?
Bosutinib: a new, safer TKI for frontline CML
Asciminib has the potential to succeed where other TKIs have failed in CML
Key points in patient support across hematological oncology
DESTINY: achieving TFR by de-escalating therapy in CML